Closed · EP-IDS-10-003 · CFDA 93.360 · Discretionary

Development and Sustainable Manufacturing of Adjuvanted Pandemic Influenza Vaccines in Developing Countries

Federal grant opportunity posted by Assistant Secretary for Preparedness and Response, cataloged on Grants.gov.

$650K-$2M
Award range
Closed
Status
August 6, 2010
Close date
-
Expected awards

The verdict

Development and Sustainable Manufacturing of Adjuvanted Pandemic Influenza Vaccines in Developing Countries is a closed discretionary listing from Assistant Secretary for Preparedness and Response that offered $650,000 -- $2,000,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 66 other opportunities from Assistant Secretary for Preparedness and Response.

$650K-$2M
award range
Closed
application status
93.360
CFDA program
66
other opportunities from Assistant Secretary for Preparedness and Response

Archived opportunity record

Development and Sustainable Manufacturing of… is closed (last close August 6, 2010). Check the agency catalog for replacement NOFOs. Assistant Secretary for Preparedness and Response still indexes 66 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed August 6, 2010

Posted Jun 18 Closes Aug 6

Instrument

Cooperative Agreement

Description

The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. BARDA maintains business collaborations by means of grants, cooperative agreements, and contracts with the public and private sectors, domestically and internationally.Both the H5N1 avian influenza virus and the recent H1N1 swine influenza virus raise the possibility of a massive and deadly influenza pandemic. It is widely accepted that an effective pandemic vaccine could significantly decrease the mortality and morbidity associated with the next pandemic. Unfortunately, the overall global production capacity is insufficient to meet the expected pandemic response needs. Furthermore, developing countries are completely dependent on the availability and accessibility of vaccine manufactured by multinational producers in developed countries. One possible solution to this problem is to increase influenza vaccine production capacity in both developed and developing countries to better address the impact of a pandemic influenza outbreak. The World Health Organization (WHO) and the Program for Appropriate Technologies in Health (PATH) represent important stakeholders in the identification of developing countries with viable vaccine manufacturing capabilities and in providing those institutions with technical guidance and support. In FY 2006-2008, with a total of $24.4 million, BARDA, through a cooperative agreement with World Health Organization (WHO), supported the accelerated development and production of H5N1 influenza human vaccine in Vietnam, Thailand, Indonesia, India, Mexico, Brazil, Egypt, Romania, and Serbia. BARDA funding addresses global and specific country needs for training, laboratory equipment, manufacturing process development, development and validation of product release assay methods, clinical sample analysis, production of pilot lots, scale-up development for vaccine manufacturing, vaccine production equipment, and eventual commercial scale manufacturing of H5N1 vaccines for clinical trials and pandemic usage. To increase pandemic influenza vaccine capacity, an additional approach is to expand the number of doses available by significantly enhancing immunogencity, thereby decreasing the amount of vaccine antigen required in each dose to induce protective immunity (referred to as “antigen sparing”). Another antigen sparing strategy is to enhance immunity such that only one vaccination dose is needed to elicit protective immunity. Potential antigen sparing products may include adjuvants, immunostimulants, immune cytokines, or other biologicals formulated with or co-administered with influenza vaccine antigens. These antigen sparing strategies could potentially extend the pandemic influenza vaccine supply several-fold, substantially improving the ability to rapidly protect local populations in a pandemic and potentially leading to vaccine availability regionally and internationally for countries yet to have domestic production. These are important strategies toward increasing local and regional vaccine supplies and improving real-time response in an influenza pandemic. Strategies that can be implemented by influenza vaccine manufacturers in developing countries unencumbered by intellectual property restrictions and whose platform is not tied to a specific manufacturer or product would be highly advantageous in developing countries. For an antigen sparing strategy to contribute to global pandemic preparedness and response, that technology must be: 1) effective in decreasing the amount of vaccine antigen required to induce a protective immune response; 2) licensed and available at the time of the pandemic; and 3) feasible for implementing a mass vaccination program. Unfortunately, developing countries do not have access to appropriate adjuvant technology in their pandemic influenza development and manufacturing.

Catch-all / unrestricted eligibility mark · EP-IDS-10-003

Grants.gov marks Development and Sustainable Manufacturing of… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Other · Science and Technology / R&D (O;ST). This eligibility-code string dominates the Assistant Secretary for Preparedness and Response book (28 peers, 42% of 67).

Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

Chuong Huynh Project Officer Phone 202-205-4520

What to do next

Development and Sustainable Manufacturing of… is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 93.360 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants